Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis PRESS RELEASE GlobeNewswire Aug. 6, 2019, 01:00 AM ...

Sanofi ’s prescription drug Dupixent confirmed its promise in helping patients with a chronic lung disorder, potentially speeding the process for the blockbuster medicine to gain another avenue ...

Sanofi and Regeneron are investigating another COPD candidate, itepekimab, for former smokers, which make up roughly 70% of the disease population. Itepekimab is due for a readout in 2025 ...

Looking ahead for 2019, CEO Olivier Brandicourt said Sanofi is pleased with Dupixent’s U.S. payer progress, with more than 90% of adult asthma patients now covered.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...